前列腺癌复发与转移的现行影像技术及影像表现谱:图解综述
本文综述了前列腺癌根治性局部治疗后复发与转移的影像学评估,涵盖传统影像(CT、骨闪烁显像)与先进影像(多参数MRI、PET/CT或PET/MRI使用碳11胆碱、氟18氟昔洛韦及研究性镓68 PSMA示踪剂)的优势与局限,并系统回顾了局部复发与转移性疾病的临床及影像特征。
要点
- 多参数MRI对前列腺切除床局部复发及放疗或热消融后原位复发检测更敏感,且可引导靶向活检确诊。
- PET/CT或PET/MRI使用碳11胆碱或氟18氟昔洛韦对早期转移(如小体积淋巴结转移)诊断的敏感度和特异度显著提高。
- 转移最常见于骨和淋巴结,其他器官包括肝、肺、胸膜、肾上腺、输尿管、腹膜、阴茎、睾丸和脑膜。
核心结论
- 随着影像模态和技术的进步,对复发性前列腺癌的更准确早期检测、定位和表征已成为可能。
研究设计与样本
- 本文为图解综述,系统性回顾了传统和先进影像模态在前列腺癌复发评估中的优势与局限,以及局部复发和转移性疾病的临床与影像特征;原文未报告系统检索范围与纳入文献数量。
关键影像表现/征象
- 转移性前列腺癌最常累及骨和淋巴结,其次为肝、肺、胸膜、肾上腺、输尿管、腹膜、阴茎、睾丸和脑膜。
- 多参数MRI可检测前列腺切除床局部复发以及放疗或热消融后前列腺腺体内的原位复发。
- 多参数MRI检出的病灶可进行靶向活检以明确复发诊断。
- PET/CT或PET/MRI使用碳11胆碱或氟18氟昔洛韦对早期转移性疾病(如小体积淋巴结转移)诊断的敏感度和特异度显著提高。
- 一系列研究性镓68 PSMA放射性PET示踪剂也显示出对早期转移性疾病诊断的敏感度和特异度显著提高。
诊断标准与关键数值
- 原文未报告具体的敏感度、特异度、AUC、阈值或分级标准数值。
临床应用与阅片要点
- 初始根治性局部治疗后PSA水平复发常是复发的首个征象,但PSA复发无法准确区分局部复发、转移性疾病或两者并存。
- 传统影像包括CT和骨闪烁显像长期作为标准诊疗,但检测早期局部复发或转移性疾病的敏感性有限。
- 多参数MRI对检测前列腺切除床局部复发及放疗或热消融后原位复发更敏感,且可引导靶向活检。
- PET/CT或PET/MRI使用碳11胆碱或氟18氟昔洛韦对早期转移性疾病(如小体积淋巴结转移)诊断的敏感度和特异度显著提高。
- 研究性镓68 PSMA放射性PET示踪剂也显示出对早期转移性疾病诊断的敏感度和特异度显著提高。
局限性
- 传统影像包括CT和骨闪烁显像检测早期局部复发或转移性疾病的敏感性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Relapsing level of prostate-specific antigen (PSA) after initial curative-intent local therapy for organ-confined prostate cancer is often the first sign of recurrence. However, PSA level recurrence does not enable accurate differentiation of locally recurrent tumor from metastatic disease or a combination of both. Metastatic prostate cancer most frequently involves bones and lymph nodes, followed by other organs such as the liver, lung, pleura, adrenal gland, ureter, peritoneum, penis, testis, and meninges. Conventional imaging including CT and bone scintigraphy has long been the standard of care but has limited sensitivity in depicting early local recurrence or metastatic disease. Multiparametric MRI has been shown to be more sensitive in detecting locally recurrent tumor in the prostatectomy bed as well as in situ recurrence in a prostate gland that has been treated with radiation therapy or thermal ablation. In addition, lesions detected with multiparametric MRI may be amenable to targeted biopsy for definitive diagnosis of recurrence. PET/CT or PET/MRI using the U.S. Food and Drug Administration (FDA)-approved tracers carbon 11 choline or fluorine 18 fluciclovine has demonstrated markedly increased sensitivity and specificity for diagnosis of early metastatic disease such as small-volume lymph node metastasis, as have a range of investigational gallium 68 prostate-specific membrane antigen (PSMA) radioactive PET tracers. With recent advances in imaging modalities and techniques, more accurate early detection, localization, and characterization of recurrent prostate cancer have become possible. The authors present a contemporary review of the strengths and limitations of conventional and advanced imaging modalities in evaluation of patients with recurrent prostate cancer and a systematic review of the clinical and imaging features of locally recurrent and metastatic disease.©RSNA, 2020See discussion on this article by Barwick and Castellucci.
引用
- Tanaka T, Yang M, Froemming AT, et al. Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review. Radiographics. 2020. PMID: 32196428. doi:10.1148/rg.2020190121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。